Joe Jimenez (Steffen Schmidt/Keystone via AP,file)
November 7, 2024 07:03 AM EST
Startups
Deals
China

Joe Jimenez's lat­est Adi­tum com­pa­ny lines up T cell en­gager from Chi­na

Kyle LaHucik

Senior Reporter

Joe Jimenez’s Adi­tum Bio, an in­vest­ment firm that builds com­pa­nies around in-li­censed as­sets, is go­ing af­ter one of the hottest new ar­eas for its lat­est …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

Up­dat­ed: No­vo’s 23% weight loss with Ca­griSe­ma falls short of high ex­pec­ta­tions, new tri­al planned

Sofinno­va out­lines $550M fund af­ter IPOs and M&A deals

FDA ap­proves Hu­ma­cyte’s lab-grown blood ves­sels in mile­stone for re­gen­er­a­tive med­i­cine

Ac­cel­er­at­ed ap­proval brings Pfiz­er's BRAF in­hibitor to first-line pa­tients

Ex­clu­sive: Flori­da can­cer biotech rais­es $100M Se­ries A

A service from the Financial Times